Abbott opens R&D facility, invests $53M

Abbott has opened a new Formulation Development Center at its Illinois headquarters. At the R&D facility, researchers will take candidate molecules and formulate them into tablets and capsules for use in in pre-clinical and clinical studies. "The new formulation center is a clear example of Abbott's commitment to advancing scientific innovation," said John Leonard, M.D., senior vice president, Pharmaceuticals, Research and Development, Abbott. "With the growing number of compounds in Abbott's pipeline, the new center utilizes the latest technology to accelerate the development of future medicines."

- see Abbott's release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.